Free Trial
NASDAQ:TRML

Tourmaline Bio Q1 2025 Earnings Report

Tourmaline Bio logo
$23.31 +0.25 (+1.08%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$23.34 +0.03 (+0.13%)
As of 08/22/2025 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio EPS Results

Actual EPS
-$0.89
Consensus EPS
-$0.91
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Tourmaline Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tourmaline Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 2, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Tourmaline Bio's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tourmaline Bio Earnings Headlines

FY2025 EPS Estimates for Tourmaline Bio Lowered by Analyst
Leerink Partnrs Expects Higher Earnings for Tourmaline Bio
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
Tourmaline Bio Q3 EPS Estimate Raised by Lifesci Capital
Wedbush Estimates Tourmaline Bio's Q3 Earnings (NASDAQ:TRML)
See More Tourmaline Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email.

About Tourmaline Bio

Tourmaline Bio (NASDAQ:TRML) operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

View Tourmaline Bio Profile

More Earnings Resources from MarketBeat